Atomo Diagnostics Limited (ASX:AT1)

Market Cap	12.14M
Revenue (ttm)	4.22M
Net Income (ttm)	-6.45M
Shares Out	639.20M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	883,724
Average Volume	978,150
Open	0.0210
Previous Close	0.0200
Day's Range	0.0180 - 0.0210
52-Week Range	0.0160 - 0.0440
Beta	0.89
RSI	51.32
Earnings Date	Apr 30, 2025

About Atomo Diagnostics

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers rapid diagnostic test devices for HIV screening, pregnancy test, and respiratory test. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 85
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AT1

Financial Performance

In 2024, Atomo Diagnostics's revenue was 4.09 million, an increase of 60.65% compared to the previous year's 2.54 million. Losses were -6.85 million, -31.23% less than in 2023.